Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of MB02 (Bevacizumab Biosimilar) vs Avastin in Healthy Volunteers
NCT03293654Phase 1Completed
- Sponsor
- mAbxience
- Start
- Dec 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pemetrexed in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (3 arms), sponsored by mAbxience. Primary endpoints: Maximum Observed Serum Concentration at Day 100 and Area Under the Serum Concentration-time Curve From Time Zero to Infinity at Day 100. Started Dec 2017; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03293654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03293654.